title: Molecular epidemiology of HTLV-I-associated non-Hodgkin's lymphomas in Jamaica.
abstract: As part of epidemiologic studies of human T-lymphotropic virus (HTLV)-I-associated malignancies in Jamaica, the authors evaluated 26 patients with non-Hodgkin's lymphoma for the presence of integrated HTLV-I provirus in their malignant cells. Fifteen of 26 patients had integrated provirus. All 15 also were HTLV-I antibody positive. Eleven patients did not have integrated provirus, and all 11 were antibody negative. All of the antibody-positive cases had onset of their disease in adulthood (age range, 21-57 years) as opposed to the broad age range of negative cases (4-66 years). Clinical features which were more common in provirus positive than negative patients included leukemic phase, skin involvement, and hypercalcemia, which are all features frequently seen in HTLV-I-associated adult T-cell leukemia/lymphoma (ATLL). The presence of skin involvement, circulating malignant cells, abnormal liver function tests, or the presence of two or more of these four features were statistically significantly different between virus-positive and virus-negative cases. Although the survival of positive cases (6 months) was shorter than that of negative cases (9 months), this was not statistically significant. The only significant determinant of survival was hypercalcemia, with those who developed hypercalcemia at some point in their disease course, independent of their HTLV-I status, surviving a mean of 5 months as compared to a mean of 17.5 months in those who never became hypercalcemic. The six HTLV-I-positive lymphomas that underwent cell typing were all primarily OKT4 positive, whereas two HTLV-I antibody-negative cases that were typed were B-cell lymphomas.
authors.affiliation: Environmental Epidemiology Branch, National Cancer Institute, Bethesda, MD 20892.
authors.forename: J W
authors.initials: JW
authors.lastname: Clark
authors.forename: C
authors.initials: C
authors.lastname: Gurgo
authors.forename: G
authors.initials: G
authors.lastname: Franchini
authors.forename: W N
authors.initials: WN
authors.lastname: Gibbs
authors.forename: W
authors.initials: W
authors.lastname: Lofters
authors.forename: C
authors.initials: C
authors.lastname: Neuland
authors.forename: D
authors.initials: D
authors.lastname: Mann
authors.forename: C
authors.initials: C
authors.lastname: Saxinger
authors.forename: R C
authors.initials: RC
authors.lastname: Gallo
authors.forename: W A
authors.initials: WA
authors.lastname: Blattner
mesh_terms: D000914:Antibodies, Viral / Q000032:analysis; D004279:DNA, Viral / Q000032:analysis; D017977:Deltaretrovirus / Q000276:immunology / Q000302:isolation & purification*; D006689:Hodgkin Disease / Q000453:epidemiology / Q000276:immunology / Q000382:microbiology / Q000401:mortality; D006801:Humans; D006934:Hypercalcemia / Q000401:mortality; D007563:Jamaica; D007945:Leukemia, Lymphoid / Q000453:epidemiology / Q000276:immunology / Q000382:microbiology / Q000401:mortality; D015470:Leukemia, Myeloid, Acute / Q000453:epidemiology / Q000276:immunology / Q000382:microbiology / Q000401:mortality; D008199:Lymphadenitis / Q000453:epidemiology / Q000276:immunology / Q000382:microbiology / Q000401:mortality; D008228:Lymphoma, Non-Hodgkin / Q000453:epidemiology* / Q000276:immunology / Q000382:microbiology / Q000401:mortality; D011533:Proviruses / Q000276:immunology / Q000302:isolation & purification*
chemical_list: D000914:Antibodies, Viral; D004279:DNA, Viral